Fosun Pharmaceutical announced that on November 17, 2026, the board of directors of the company received a proposal to repurchase A-shares listed in China through centralized bidding, with a total repurchase capital of not less than 250 million yuan and no more than 500 million yuan. The repurchase price does not exceed 150% of the average A-share transaction price in the 30 trading days before the board of directors approved the buyback plan. The repurchase period does not exceed 12 months from the date the board of directors reviews and approves the repurchase plan. The repurchase shares are intended to be used for convertible debt-for-share swaps, equity incentives, or employee share ownership plans, etc. Review and approval shall prevail. Chen Yuqing promised that the board of directors would vote in favor of the repurchase plan. The company's shares were not traded within the first 6 months of the proposal, and there are no plans to increase or decrease holdings between the proposal and the announcement of the repurchase results. The repurchase is still subject to internal review procedures, and there is uncertainty.

Zhitongcaijing · 1d ago
Fosun Pharmaceutical announced that on November 17, 2026, the board of directors of the company received a proposal to repurchase A-shares listed in China through centralized bidding, with a total repurchase capital of not less than 250 million yuan and no more than 500 million yuan. The repurchase price does not exceed 150% of the average A-share transaction price in the 30 trading days before the board of directors approved the buyback plan. The repurchase period does not exceed 12 months from the date the board of directors reviews and approves the repurchase plan. The repurchase shares are intended to be used for convertible debt-for-share swaps, equity incentives, or employee share ownership plans, etc. Review and approval shall prevail. Chen Yuqing promised that the board of directors would vote in favor of the repurchase plan. The company's shares were not traded within the first 6 months of the proposal, and there are no plans to increase or decrease holdings between the proposal and the announcement of the repurchase results. The repurchase is still subject to internal review procedures, and there is uncertainty.